Laboratorios Farmaceuticos Rovi Balance Sheet Health
Financial Health criteria checks 5/6
Laboratorios Farmaceuticos Rovi has a total shareholder equity of €523.8M and total debt of €81.8M, which brings its debt-to-equity ratio to 15.6%. Its total assets and total liabilities are €778.7M and €254.9M respectively. Laboratorios Farmaceuticos Rovi's EBIT is €178.1M making its interest coverage ratio -556.6. It has cash and short-term investments of €13.1M.
Key information
15.6%
Debt to equity ratio
€81.77m
Debt
Interest coverage ratio | -556.6x |
Cash | €13.09m |
Equity | €523.78m |
Total liabilities | €254.88m |
Total assets | €778.66m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: LABF.F's short term assets (€485.4M) exceed its short term liabilities (€191.2M).
Long Term Liabilities: LABF.F's short term assets (€485.4M) exceed its long term liabilities (€63.6M).
Debt to Equity History and Analysis
Debt Level: LABF.F's net debt to equity ratio (13.1%) is considered satisfactory.
Reducing Debt: LABF.F's debt to equity ratio has increased from 10.1% to 15.6% over the past 5 years.
Debt Coverage: LABF.F's debt is well covered by operating cash flow (127.5%).
Interest Coverage: LABF.F earns more interest than it pays, so coverage of interest payments is not a concern.